Massive diabetes biobank aims to predict kidney and heart risks

NCT ID NCT05282680

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is building a large biobank of health information and blood samples from 48,000 people with diabetes in Hong Kong. Researchers will analyze genetic and other markers to find better ways to predict serious complications like kidney failure, heart disease, and stroke. The goal is to improve early detection and personalized treatment for diabetes-related problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict who will develop serious diabetes complications, enabling earlier treatment and personalized care.
What could go wrong
This is an observational study, not a treatment trial. It may not identify reliable biomarkers, and any findings will need years of further research before they can help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Prince of Wales Hospital

    Shatin, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.